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Purpose: To investigate the potential inhibitory effects of RNA interference-mediated knockdown  of  neuropilin-2
(NP2) on inflammation-induced corneal hemangiogenesis and lymphangiogenesis, and whether selective inhibition of
lymphangiogenesis on vascularized recipient beds before transplantation improves the graft survival.
Methods: Mouse lymphatic endothelial cells were transfected with the plasmid expressing artificial microRNA (amiRNA)
against mouse NP2, and the down-regulation of VEGF-C-induced NP2 expression by NP2 amiRNA was evaluated by
real-time PCR and western blot assays. Next, NP2 amiRNA or negative control amiRNA was injected intrastromally into
BALB/c mouse model of suture-induced corneal neovascularization three days after surgery. Corneas were harvested 1
week after suture placement and the formation of lymphatic and blood vessels as well as the recruitment of macrophage
was evaluated by immunohistochemical staining. The neovascularized graft beds treated by NP2 amiRNA or control then
served as recipients of orthotopic corneal transplants, and age-matched C57BL/6 donors were used. Corneal allografts
were examined twice a week for 8 weeks, and graft clarity was quantified by means of an opacity score.
Results: VEGF-C-induced NP2 expression at both mRNA and protein levels was significantly suppressed by NP2
amiRNA  in  mouse  lymphatic  endothelial  cells.  Intrastromal  administration  of  NP2  amiRNA  reduced  corneal
lymphangiogenesis by 45% versus control (p=0.015), but corneal hemangiogenesis (p=0.815) and the recruitment of CD11
antigen-like family member B (CD11b)-positive macrophage (p=0.589) were unchanged. Kaplan–Meier survival analysis
revealed a better graft survival rate in the vascularized recipient beds pre-treated by NP2 amiRNA in comparison to controls
(p=0.014).
Conclusions:  Knockdown  of  NP2  improves  corneal  graft  survival  by  selectively  inhibiting  lymphangiogenesis  in
vascularized beds before transplantation. Thus our results open new treatment options for transplant rejection and other
lymphatic disorders.
Currently corneal transplantation is the only treatment for
many  severe  cornea  diseases  including  corneal  injury,
infection, degeneration and inherited diseases. The 5-year
survival rate of low-risk keratoplasty (with a preoperatively
avascular recipient bed) is around 90%, even without human
leukocyte antigen matching [1]. In contrast, the survival rate
of  high-risk  keratoplasty  (with  a  pathologically
prevascularized corneal bed) decreases significantly to below
50%  due  to  immune-mediated  rejection  [2,3].  Preexisting
corneal  blood  (hemangiogenesis)  and  lymphatic
(lymphangiogenesis)  vessels  in  recipient  beds  have  been
identified  as  strong  risk  factors  for  immune  rejection
following corneal transplantation [3,4]. The blood vasculature
drains oxygen, nutrients, and cells to corneas whereas the
lymphatic vessels transport donor-derived antigen-presenting
cells and antigenic materials to the draining lymph nodes, thus
inducing an immune response against an allogeneic transplant
[5].  Recent  studies  on  corneal  hemangiogenesis  has
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demonstrated  that  anti-hemangiogenic  strategies  may
promote graft survival both in the low-risk as well as in the
high-risk murine corneal transplantation [6,7]. Nevertheless,
several  studies  suggest  that  lymphangiogenesis  plays  an
important role in the induction of alloimmunity after organ
transplantation  [5].  Using  the  murine  model  of  corneal
transplantation, it was shown that afferent corneal lymphatics
may be equal, or even more important than efferent corneal
blood vessels in modulating allograft rejection [8].
Although  endogenous  lymphangiogenic  inhibitors
remain to be discovered, several secreted factors that promote
corneal  lymphangiogenesis  have  been  identified  recently,
including members of the vascular endothelial growth factor
(VEGF)  family  [9],  fibroblast  growth  factor-2  [10],
angiopoietin [11], platelet derived growth factor–BB [12],
hepatocyte growth factor [13], and insulin-like growth factors
[14].  Among  these  corneal  lymphangiogenic  factors,
lymphatic growth factors VEGF-C and its receptor vascular
endothelial  growth  factor  receptor  (VEGFR)-3  are  best
studied. VEGFR-3 has been shown to be expressed in corneal
epithelium  [15]  and  corneal  dendritic  cells  [16],  and
VEGFR-3  expression  is  upregulated  in  inflamed  corneas
[17]. Anti-lymphangiogenic strategies targeting VEGFR-3-
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2354mediated signaling specifically inhibit lymphangiogenesis in
inflammatory  corneal  neovascularisation  [18]  and
significantly  suppress  corneal  transplant  rejection  [17].
VEGF-C, a ligand of VEGFR-3, has been shown to be able to
induce  lymphatic  vessel  growth  in  the  cornea  [9,10].  In
addition,  VEGF-C  is  upregulated  by  proinflammatory
cytokines in macrophages, dendritic cells, neutrophils and
mast cells [19], suggesting that it stimulates lymphatic vessel
growth during inflammation.
Neuropilin-2 (NP2) is a transmembrane protein initially
identified as a receptor for class-3 semaphorin subfamily for
neuronal guidance [20]. However, NP2 also acts as a co-
receptor for VEGF-C [21] and is implicated in embryonic
vessel development [22]. More recent studies have revealed
that NP2 functions in tumor lymphangiogenesis and tumor
metastasis [23]. This raises the intriguing possibility that NP2
may be a modulator of corneal lymphangiogenesis and that
interfering with the afferent arm of the immune response by
blocking NP2 may reduce the risk of corneal graft rejection.
Therefore,  in  this  study,  we  employed  artificial
microRNA  (amiRNA)  to  knockdown  NP2  in  lymphatic
endothelial  cells  (LECs)  and  further  achieved  selective
inhibition  of  lymphangiogenesis  in  suture-induced
vascularized corneal beds by intracorneal administration of
NP2 amiRNA. Finally we established a mouse model of high-
risk orthotopic corneal transplantation to demonstrate that
selective inhibition of lymphangiogenesis mediated by NP2
knockdown  led  to  improved  high-risk  graft  survival  on
vascularized recipient beds before transplantation.
METHODS
Construction of plasmid: Using the Invitrogen’s RNAi web
design  tool,  we  designed  a  potential  mouse  NP2-specific
targeting sequence as described previously [24]. A BLAST
analysis  was  performed  to  ensure  the  designed  sequence
would have no substantial homology to sequences in other
vertebrate  genes.  The  sequence  of  oligonucleotides  was
shown in Figure 1A. These oligonucleotides were annealed
and ligated into the pcDNATM6.2-GW/EmGFP-miR vector
(Invitrogen,  Carlsbad,  CA)  to  construct  NP2-targeting
amiRNA (NP2-amiR). The negative control plasmid, negative
amiRNA  (neg-amiR;  Invitrogen),  was  created  using  a
sequence predicted not to target any known vertebrate genes.
Cell culture and transfection: The mouse LECs were kindly
provided  by  Dr.  Annunciata  Vecchi  (Istituto  Clinico
Humanitas,  Rozzano,  Italy)  and  cultured  as  described
previously [25]. Cells at passages 14–16 were selected for
further experiments. One day before transfection, 1.5×105
cells  were  seeded  into  6-well  plates.  The  cells  were  then
transfected with NP2-amiR or neg-amiR using Lipofectamine
PLUS  reagent  (Invitrogen)  and  selected  with  5  ug/ml
blasticidin  (Invitrogen).  The  mouse  LECs  were  then
stimulated by 200 ng/ml VEGF-C (Genentech, South San
Francisco, CA), and quantitative real-time PCR and western
blot were performed 6 h after stimulation.
Quantitative real-time PCR: Total RNA was extracted using
TRIzol reagent (Invitrogen) according to the manufacturer’s
instruction. Total RNA (500 ng) was reverse transcribed for
45 min at 45 °C using TaKaRa RNA PCR Kit (AMV) Ver.3.0
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Figure 1. NP2-targeting artificial microRNA (amiRNA) down-regulates VEGF-C induced NP2 expression in mouse LECs. A: Double-stranded
oligonucleotide encoding a pre-miRNA against mouse NP2. B: Mouse LECs were transfected with NP2-targeting amiRNA (NP2-amiR),
negative amiRNA (neg-amiR) or mock-transfected (parental), 48 h after transfection NP2 expression was detected by western blot using anti-
NP2 antibody. The images were representative of three independent experiments. β-actin was used as loading control. C: Quantitative real-
time PCR analysis of NP2 mRNA in parental, negative amiRNA or NP2 knockdown cells. Data were presented as the mean transcript
expression normalized to GAPDH of three independent samples±SEM (n=3 per condition). The asterisk indicates a p<0.01 versus parental
control. D: ELISA analysis of NP2 level in mouse corneas at the time point (7 days after injury; n=9 per group). All measurements were
performed in duplicate. Bars, SEM. The asterisk indicates a p<0.05 versus saline control.(TaKaRa, Dalian, China). EvaGreen quantitative PCR was
performed in an ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA). Synthesized cDNA
(1 μl) of each reaction was used in a 25 μl reaction volume
containing 1.25 ul of EvaGreenTM dye (Biotium, Hayward,
CA). Results were derived from the comparative threshold
cycle method and normalized by glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH)  as  an  internal  control.  The
following primers were used for real-time PCR: NP2, 5′-GTG
TAC GAC CAT GCC AAG TG-3′ (sense), 5′-TGA CCC
AAA GGA GTT TGC TT-3′ (antisense); GAPDH, 5′-GTA
TT GGG CGC CTG GTC ACC-3′ (sense), 5′-CGC TCC TGG
AAG ATG GTG ATG G-3′ (antisense).
Western blot analysis: Total protein extracts were prepared
by washing cells with phosphate-buffered saline (PBS) and
lysing in ice-cold RIPA lysis buffer (Beyotime, Shanghai,
China)  with  the  addition  of  protease  inhibitors.  After
separation by 10% sodium dodecyl sulfate-PAGE, proteins
were electro-transferred onto nitrocellulose membranes. The
membranes were incubated in blocking solution (2% BSA in
Tris-buffered  saline  with  Tween-20)  for  1  h  at  room
temperature, then incubated with rabbit polyclonal anti-NP2
antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
overnight at 4 °C. After washing and blocking, the membranes
were  further  incubated  with  corresponding  horseradish
peroxidase-conjugated  second  antibody  for  1  h  at  room
temperature,  and  developed  using  enhanced
chemiluminescence  detection  reagents  (Applygen
Technologies Inc., Beijing, China). Quantitative analysis of
the  bands  was  performed  with  LabWorksTM  Image
Acquisition and Analysis Software (GDS-8000 system; UVP,
Cambridge, UK).
Animals and anesthesia: Six- to eight-week-old male BALB/
c and C57BL6 mice were purchased from the Institute of
Tumor Research (Harbin, China). Animals were treated in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. Mice were anesthetized
with  a  mixture  of  ketamine  and  xylazine  (120  mg/kg
bodyweight and 20 mg/kg bodyweight, respectively).
Suture-induced  corneal  neovascularization  and  corneal
intrastromal  injections:  Inflammatory  corneal
neovascularization was induced by corneal suture placement,
as  described  previously  [26]  with  some  modifications.
Briefly, a 2-mm corneal trephine was gently placed on the
cornea to mark the central corneal area. Eight interrupted 11–
0 nylon sutures (Huawei, Hangzhou, China) wer    e placed  in
the site where the corneal trephine marked. Corneal sutures
were removed after 7 days. The in vivo delivery of NP2-amiR
or  neg-amiR  to  the  cornea  was  performed  as  described
previously [27]. Briefly, 1.0 ug plasmid in 2 ul of PBS was
injected into the corneal stroma using a 33-gauge Hamilton
syringe (Hamilton Co., Reno, NV). Injections were performed
on day 3 after suture placement. One week later, penetrating
corneal transplantations were performed using age-matched
C57BL/6 donors.
High-risk corneal transplantation and the evaluation of graft
survival: Mouse orthotopic corneal penetrating keratoplasty
was performed as described previously [4]. Briefly, the central
corneal area of C57BL6 donor was excised using a 2.0-mm
mouse trephine and Vannas scissiors. The prevascularized
graft bed of BALB/c recipient was also prepared by trephining
the right eye and the donor graft was sewn into place using 8
interrupted  11–0  nylon  sutures  (Sharppoint;  Vanguard,
Houston, Tex). Corneal transplant sutures were removed after
7 days and grafts were then examined by slitlamp microscopy
twice weekly over 56 days. All grafted eyes with surgical
complications  (hyphema,  cataract,  infection,  significant
anterior synechiae, or loss of anterior chamber) were excluded
from the study. The degree of corneal grafts for opacity was
graded and the survival rates were assessed by Kaplan–Meier
analysis [28]. Grafts with an opacity score of 2 or higher after
2 weeks or an opacity score of 3 or higher at 2 weeks were
regarded as rejected.
Immunohistochemistry: Corneal whole mount preparations
were done as previously described [7]. Briefly, corneas were
dissected from the eye behind the corneal limbus, rinsed in
PBS and fixed in acetone for 1 h at room temperature. Then
the corneas were washed in PBS and blocked in 2% BSA in
PBS for 2 h at room temperature. Afterward, the corneas were
incubated with rabbit anti-mouse LYVE-1 antibody (1:500;
Abcam, Cambridge, UK) overnight at 4 °C. On the 2nd day,
the  tissue  was  washed,  blocked  and  stained  with  FITC-
conjugated rat anti-mouse CD31 antibody (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA) overnight at 4 °C. On the 3rd
day, the specimens were incubated with CY3-conjugated goat
anti-rabbit second antibody (1:100; Sigma, St. Louis, Mo.) for
1  h  at  room  temperature.  To  detect  the  recruitment  of
macrophages into the inflamed cornea, FITC-conjugated rat
anti-mouse CD11b antibody (BD PharMingen, San Diego,
CA) was used. To ensure specificity, negative controls were
performed by omitting the primary antibody. Fluorescence
microscopy  and  photography  was  done  using  the  BX51
camera  (Olympus  Optical  Co.,  Hamburg,  Germany).  The
immunofluorescence  was  quantified  using  NIH  Image
software.
Determination of NP2 levels by ELISA: Corneas harvested for
ELISA were homogenized in 1.0 ml of sterile PBS containing
0.05%  v/v  Triton-X  100  at  4  °C.  The  supernatant  was
collected, and total protein was determined with a Bradford
protein  assay.  The  level  of  NP2  in  corneal  lysates  was
determined by ELISA kit for murine NP2 (R&D systems,
Minneapolis,  MN)  according  to  the  manufacturer’s
instructions. All measurements were performed in duplicate.
Statistical analysis: All statistical analyses were performed
using  SPSS  13.0  software  (SPSS,  Chicago,  IL).  The
differences  between  groups  were  compared  by  using
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U  test  for  all  in  vivo  studies.  A  p<0.05  was  considered
significant.
RESULTS
NP2-targeting  amiRNA  suppresses  VEGF-C-induced  NP2
expression in mouse LECs: Western blot assay demonstrated
that NP2-amiR but not negative control neg-amiR specially
inhibited  NP2  expression  in  mouse  LECs  stimulated  by
VEGF-C  (Figure  1B).  Furthermore,  real-time  quantitative
PCR assay confirmed the significant inhibition of NP2 mRNA
expression in NP2-amiR treated cells compared with parental
control cells (p=0.005, Figure 1C).
Intrastromal delivery of NP2-targeting amiRNA suppresses
corneal NP2 expression: To further evaluate whether NP2-
amiR could inhibit NP2 expression in vivo, corneas were
subjected to intrastromal delivery of NP2-amiR and harvested
on day 7 after suture placement. NP2 ELISA showed that NP2
concentration was 591.14±57.51 pg/ml in saline control mice,
605.58±52.58  pg/ml  in  neg-amiR  treated  mice  (p=0.606,
compared  to  control),  and  372.62±50.89  pg/ml  in  mice
injected  with  NP2-amiR  (p=0.031,  compared  to  control,
Figure  1D).  These  data  confirmed  that  the  intrastromal
delivery of NP2-amiR resulted in reduced NP2 expression.
Intrastromal  delivery  of  NP2-targeting  amiRNA  inhibits
corneal  lymphangiogenesis:  Corneal  suture  placement
induced a robust neovascular response which emerged from
day 3 and reached suture placement sites at day 7 after suture
injury  (Figure  2A-C).  We  investigated  the  effect  of
intrastromal injection of NP2-amiR on the outgrowth of blood
and  lymphatic  vessels  in  the  suture-induced  corneal
neovascularisation assay. The densities of Platelet Endothelial
Cell Adhesion Molecule-1 (CD31)-positive blood vessels and
lymphatic vessel endothelial receptor-1 (LYVE-1)-positive
lymphatic vessels were detected by immunohistochemistry on
day 7 (Figure 2D-L). Quantitative immunohistochemical and
morphometric analyses revealed that the number of lymphatic
vessels  in  mice  treated  with  NP2-amiR  was  significantly
decreased (p=0.015), whereas the number of blood vessels
showed  no  changes,  in  comparison  with  saline  control
(p=0.815, Figure 2M).
Intrastromal delivery of NP2-targeting amiRNA has no effect
on cell infiltration: To determine the effect of reduced NP2
expression on cell infiltration associated with corneal suture
injury in recipient beds immediately before transplantation,
we  next  examined  CD11  antigen-like  family  member  B
(CD11b)-positive  macrophage  infiltration  into  inflamed
corneas in mice treated with NP2-amiR. As shown in Figure
3,  there  was  no  significant  difference  in  the  number  of
inflammatory cells between mice treated with NP2-amiR and
control mice (p=0.589).
Intrastromal  delivery  of  NP2-targeting  amiRNA  in  the
recipient bed before transplantation significantly promotes
subsequent  graft  survival:  The  fact  that  afferent  corneal
lymphatics  plays  a  crucial  role  in  allograft  rejection  [8],
together  with  our  data  that  blockade  of  NP2  selectively
inhibited  corneal  lymphangiogenesis,  prompted  us  to
investigate  whether  knockdown  of  NP2  could  improve
corneal  allograft  survival.  Results  from  Kaplan–Meier
survival curves showed significantly prolonged graft survival
in the recipient beds pretreated with NP2-amiR, relative to
control beds injected with saline solution (p=0.014, Figure 4).
DISCUSSION
Increasing  evidence  suggests  that  NP2,  a  coreceptor  for
VEGFC, emerges as a potent regulator of lymphangiogenesis
in embryonic vessel development, tumor lymphangiogenesis
and  metastasis.  However,  the  effect  of  NP2  blockade  on
immunomodulation following transplantation has not been
investigated. To our knowledge, our findings for the first time
demonstrate  that  RNA  interference-mediated  blockade  of
NP2 is a potential therapeutic avenue to improve corneal
allograft  survival  by  selective  inhibition  of
lymphangiogenesis  on  vascularized  recipient  beds  before
transplantation.
Afferent lymphatic vessels (afferent arm of the immune
reflex arc), efferent blood vessels (efferent arm of the immune
reflex arc) and antigen-presenting cells such as macrophages
play major roles in the process of immunomodulation after
corneal  transplantation.  However,  in  severe  corneal
inflammatory disease, corneal lymphatic vessels and blood
vessels often grow in parallel into the cornea [29], which
makes  it  difficult  to  separate  lymphangiogenesis  from
hemangiogenesis.  Whether  hemangiogenesis  and
lymphangiogenesis contribute equally to corneal transplant
rejection has not been well studied, largely due to the difficulty
in selectively dissecting the individual contributions of these
two closely intermingled components. Our results suggest
NP2 knockdown as an effective strategy for specific inhibition
of  lymphangiogenesis  without  obvious  effects  on
hemangiogenesis.  Furthermore,  NP2  is  not  expressed  in
corneal macrophage (data not shown), and NP2 knockdown
had no apparent effect on the macrophages recruitment into
vascularized beds at the time of corneal transplantation. These
data demonstrate that decreasing NP2 expression has no direct
effect on corneal macrophages trafficking to regional lymph
nodes,  and  further  confirm  the  selective  effect  of  NP2
knockdown  in  the  inflamed  cornea.  In  the  aggregate,  our
findings indicate that NP2-targeting amiRNA may represent
a novel tool to investigate the individual properties of hem- or
lymphangiogenesis. More importantly, our results indicate
that inhibition of NP2 provides novel treatment options for
disorders  associated  with  pathological  lymphangiogenesis
without causing the corresponding complications induced by
anti-hemangiogenic effect.
In addition, our data showed that selective inhibition of
lymphangiogenesis  on  vascularized  recipient  beds  before
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2357Figure 2. Intrastromal injection of NP2-targeting amiRNA inhibits suture-induced corneal lymphangiogenesis but not hemangiogenesis. A-
C:  Representative  images  showing  that  corneal  suture  injury  induced  a  robust  neovascular  response  seven  days  after  injury.  D-L:
Representative segments of corneal whole-mounts (blood vessels in green: CD31/FITC; lymphatic vessels in red: LYVE-1/Cy3) in eyes treated
with NP2-amiR (F, I, L, n=9 mice) or neg-amiR (E, H, K, n=7 mice) compared with the saline control eyes (D, G, J, n=8 mice). Arrows:
limbus. Original magnification, 100×. M: Quantification of immunohistochemical staining in the area of CD31-possitive blood vessels and
LYVE-1-possitive lymphatic vessels. Bars, SEM. The asterisk indicates a p<0.05 versus saline control. The vasculized area of control group
was defined as 100%.
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2358transplantation  by  blockade  of  NP2  led  to  significantly
improved graft survival. Afferent lymphatic vessels act as a
conduit through which antigen-presenting cells and soluble
antigenic materials migrate to the draining lymph nodes to
induce  an  immune  rejection  [5].  Suppression  of
lymphangiogenesis in the graft bed by NP2 knockdown may
reduce the opportunity of donor-derived immune cells to enter
the lymphatic vascular system, thus mitigating the immune
response against an allogeneic transplant and leading to better
graft survival. This is in line with the finding that the absence
of  lymphatic  vessels  before  transplantation  significantly
promoted subsequent graft survival using VEGFR-3 Abs or
anti-integrin a5 small molecules [30]. These observations,
together with our current findings, led us to postulate that
corneal allograft survival can be significantly improved by the
reduction of lymphatic vessels in the recipient bed alone.
Interestingly, NP2 is actively involved in the regulation of
lymphatic  vasculature  by  modulating  VEGFR-3  signaling
[31], and blocking VEGFR-3 decreases corneal dendritic cell
trafficking  to  regional  lymph  nodes  in  a  mouse  corneal
transplantation model [17]. Thus we speculate that loss of NP2
promotes  allograft  survival  at  least  in  part  by  inhibiting
dendritic  cell  trafficking  through  VEGFR-3-mediated
signaling.
Besides the new therapeutic use for improving corneal
graft survival, our data also reveal NP2-targeting amiRNA as
a promising treatment in solid organ transplantation, as it does
not affect the blood supply, which is essential for wound
healing, nutrition, and homeostasis of the graft. Furthermore,
selective anti-lymphangiogenic therapy might be an optional
strategy  in  other  diseases  such  as  lymphatic  vascular
malformations,  lymphatic  neoplasms,  tumor
lymphangiogenesis and lymphatic metastases.
Collectively,  our  results  demonstrate  that  intracorneal
administration  of  NP2-targeting  amiRNA  selectively
inhibited  lymphangiogenesis  without  affecting
hemangiogenesis and macrophages recruitment, and Kaplan–
Meier survival analysis revealed a better graft survival rate in
the NP2-targeting amiRNA treated vascularized corneal beds
before transplantation. These data open new treatment options
for transplant rejection and other lymphatic disorders.
Figure 4. Effect of NP2 inhibition by NP2-amiR on survival of high-
risk allogeneic corneal transplants. Kaplan–Meier analysis showing
significant improvement of corneal graft survival in BALB/c corneal
beds  pretreated  with  NP2-amiR  (n=13)  before  transplantation
compared with beds pretreated with saline solution (n=15). The
asterisk indicates a p<0.05 versus saline control.
Figure 3. Intrastromal injection of NP2-
targeting amiRNA has no effect on the
recruitment  of  macrophage  into  the
cornea.  A:  Immunohistochemical
staining for CD11b in corneal whole-
mounts (n=6 mice per group). Original
magnification,  200×.  B:  Quantitative
analysis  of  immunohistochemistry
showed  that  NP2  knockdown  had  no
significant effect on the recruitment of
CD11b-positive  macrophages  into  the
cornea  immediately  before  high-risk
corneal  transplantation  (7  days  after
suture  placement).  Bars,  SEM.  The
asterisk indicates a p>0.05 versus saline
control.
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